COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES

被引：0
|
作者：
Chen, J., V [1 ]
Klein, T. M. [1 ]
Mudd, P. [2 ]
机构：
[1] Med Decis Modeling Inc, Indianapolis, IN USA
[2] Urovant Sci, Durham, NC USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK6
引用
收藏
页码：S235 / S235
页数：1
相关论文
共 50 条
  • [31] Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
    Michael J. Kennelly
    Thomas Rhodes
    Cynthia J. Girman
    Elizabeth Thomas
    Denise Shortino
    Paul N. Mudd
    [J]. Advances in Therapy, 2021, 38 : 5452 - 5464
  • [32] Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
    Edmondson, Scott D.
    Zhu, Cheng
    Kar, Nam Fung
    Di Salvo, Jerry
    Nagabukuro, Hiroshi
    Sacre-Salem, Beatrice
    Dingley, Karen
    Berger, Richard
    Goble, Stephen D.
    Morriello, Gregori
    Harper, Bart
    Moyes, Christopher R.
    Shen, Dong-Ming
    Wang, Liping
    Ball, Richard
    Fitzmaurice, Aileen
    Frenkl, Tara
    Gichuru, Loise N.
    Ha, Sookhee
    Hurley, Amanda L.
    Jochnowitz, Nina
    Levorse, Dorothy
    Mistry, Shruty
    Miller, Randy R.
    Ormes, James
    Salituro, Gino M.
    Sanfiz, Anthony
    Stevenson, Andra S.
    Villa, Katherine
    Zamlynny, Beata
    Green, Stuart
    Struthers, Mary
    Weber, Ann E.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (02) : 609 - 623
  • [33] COST EFFECTIVENESS OF SACRAL NEUROSTIMULATION FOR OVERACTIVE BLADDER IN MEXICO
    Soto, H.
    Sanchez, K.
    Escobar Juarez, Y.
    Constanzo, A.
    Ceballos, R.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A45 - A45
  • [34] Cost-effectiveness of novel therapies for overactive bladder
    Mayr, Craig A.
    Shepherd, Jonathan P.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
  • [35] The cost-effectiveness of extended release tolterodine in the management of overactive bladder in Germany and the United Kingdom
    Anderson, P
    Resch, A
    Dooley, JA
    Brüggenjürgen, B
    Zlateva, G
    [J]. VALUE IN HEALTH, 2004, 7 (06) : 797 - 798
  • [36] REAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSISREAL-WORLD ADHERENCE AND PERSISTENCE OF VIBEGRON IN PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE CLAIMS ANALYSIS
    Staskin, David
    Chastek, Benjamin
    Carrera, Adam
    Landis, Christina
    Snyder, Daniel
    Abedinzadeh, Laleh
    Bancroft, Tim
    Nesheim, Jeffrey
    [J]. NEUROUROLOGY AND URODYNAMICS, 2023, 42 : S164 - S165
  • [37] Economic Costs of Overactive Bladder in the United States REPLY
    Ganz, Michael L.
    Pashos, Chris L.
    Smalarz, Amy M.
    Krupski, Tracey L.
    Anger, Jennifer T.
    Hu, Jim C.
    Wittrup-Jensen, Kim U.
    [J]. UROLOGY, 2010, 75 (03) : 533 - 533
  • [38] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Parise, Helene
    Espinosa, Robert
    Dea, Katherine
    Anaya, Pablo
    Montoya, Giovanny
    Bin Ng, Daniel
    [J]. PHARMACOECONOMICS-OPEN, 2020, 4 (01) : 79 - 90
  • [39] Estimated economic costs of overactive bladder in the United States
    Hu, TW
    Wagner, TH
    Bentkover, JD
    LeBlanc, K
    Piancentini, A
    Stewart, WF
    Corey, R
    Zhou, SZ
    Hunt, TL
    [J]. UROLOGY, 2003, 61 (06) : 1123 - 1128
  • [40] Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
    Hélène Parise
    Robert Espinosa
    Katherine Dea
    Pablo Anaya
    Giovanny Montoya
    Daniel Bin Ng
    [J]. PharmacoEconomics - Open, 2020, 4 : 79 - 90
12345